Antipsychotic drugs: Evolving mechanisms of action with improved therapeutic benefits

Current Drug Targets: CNS and Neurological Disorders

Volumn 3, Issue 3, 2004, Pages 217-225

  Dean, B ^a,b,c   Scarr, E ^a,b  

^a FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

4560 RP; ALPHA (2,3 DIMETHOXYPHENYL) 1 [2 (4 FLUOROPHENYL)ETHYL] 4 PIPERIDINEMETHANOL; AMISULPRIDE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CLOZAPINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; HALOPERIDOL; IMIPRAMINE; MESORIDAZINE; MUSCARINIC RECEPTOR; NEUROLEPTIC AGENT; NEUROTRANSMITTER RECEPTOR; OLANZAPINE; PERPHENAZINE; PHENOTHIAZINE; PRECLAMOL; PROCHLORPERAZINE; QUETIAPINE; RISPERIDONE; SEROTONIN 2A RECEPTOR; SERTINDOLE; SULPIRIDE; THIORIDAZINE; TIOSPIRONE; TRIFLUPERIDOL; UNINDEXED DRUG; XANOMELINE; ZIPRASIDONE; ZOTEPINE;

AGRANULOCYTOSIS; COGNITION; DRUG ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG SPECIFICITY; EXTRAPYRAMIDAL SYMPTOM; HUMAN; NEUROPHARMACOLOGY; NONHUMAN; PSYCHOSIS; RECEPTOR BLOCKING; REVIEW; SUICIDE; SYMPTOMATOLOGY; TREATMENT OUTCOME;

ANIMALS; ANTIPSYCHOTIC AGENTS; BRAIN; BRAIN CHEMISTRY; CLOZAPINE; DOPAMINE AGENTS; HUMANS; MUSCARINIC AGONISTS; NEUROPHARMACOLOGY; PSYCHOTIC DISORDERS; RATS; RECEPTORS, DOPAMINE D2; SCHIZOPHRENIA; SEROTONIN AGONISTS;

EID: 3042841732     PISSN: 1568007X     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568007043337373     Document Type: Review

References (130)

1. Shorter, E. A History of Psychiatry; John Wiley & Sons, Inc.: New York, 1997.
2. Csernansky, J.G. Psychiatr. Clin. North Am., 2003, 26, 367.
3. Andreasen, N.C.; Olsen, S. Arch. Gen. Psychiatry, 1982, 39, 789.
4. Carpenter, W.T. Jr.; Buchanan, R.W. N. Engl. J. Med., 1994, 330, 681.
5. Delay, J.; Deniker, P.; Harl, J.-M. Annales medicopsychologiques, 1952, 110, 112.
6. Tohen, M.; Zarate, C.A. Jr. J. Clin. Psychiatry, 1998, 59 Suppl. 1, 38.
7. Rabins, P.V. J. Clin. Psychiatry, 1998, 59 Suppl. 13, 36.
8. Kuzuhara, S. J. Neurol., 2001, 248 Suppl. 3, III28.
9. McAllister, T.W.; Ferrell, R.B. NeuroRehabilitation., 2002, 17, 357.
10. Pantelis, C.; Lambert, T.J. Med. J. Aust., 2003, 178 Suppl. S62.
11. Conley, R.R.; Kelly, D.L. Curr. Drug Target CNS Neurol. Disord., 2002, 1, 123.
12. Kennedy, S.H.; Lam, R.W. Bipolar. Disord., 2003, 5 Suppl. 2, 36.
13. Meltzer, H.Y. Curr. Psychiatry Rep., 2002, 4, 279.
14. Carlsson, A.; Lindqvist, M. Acta Pharmac. Toxicol., 1963, 20, 140.
15. Seeman, P. Pharmacol. Rev., 1980, 32, 229.
16. Seeman, P.; Lee, T.; Chau-Wong, M.; Wong, K. Nature, 1976, 261, 717.
17. Creese, I.; Burt, D.R.; Snyder, S.H. Science, 1976, 192, 481.
18. Whitworth, A.B.; Fleischhacker, W.W. Int. Clin. Psychopharmacol., 1995, 9 Suppl. 5, 21.
19. Singh, M.M.; Kay, S.R. J. Nerv. Ment. Dis., 1975, 160, 258.
20. Meltzer, H.Y. Schizophr. Bull., 1976, 2, 10.
21. Weinberger, D.R. Trends Neurosci., 1988, 11, 367.
22. Baldessarini, R.J.; Frankenburg, F.R. N. Engl. J. Med., 1991, 324, 746.
23. Idanpaan-Heikkila, J.; Alhava, E.; Olkinuora, M.; Palva, I.P. Eur. J. Clin. Pharmacol., 1977, 11, 193.
24. Kane, J.M.; McGlashan, T.H. Lancet, 1995, 346, 820.
25. Ereshefsky, L.; Watanabe, M.D.; Tran-Johnson, T.K. Clin. Pharm., 1989, 8, 691.
26. Van Tol, H.H.; Bunzow, J.R.; Guan, B.C.; Sunahara, R.K.; Seeman, P.; Niznik, H.B.; Civelli, O. Nature, 1991, 350, 610.
27. Kramer, M.S.; Last, B.; Getson, A.; Reines, S.A. Arch. Gen. Psychiatry, 1997, 54, 567.
28. Sibley, D.R.; Monsma, F.J. Jr. Trends Pharmacol. Sci., 1992, 13, 61.
29. Hoyer, D.; Hannon, J.P.; Martin, G.R. Pharmacol. Biochem. Behav., 2002, 71, 533.
30. Ozawa, S.; Kamiya, H.; Tsuzuki, K. Prog. Neurobiol., 1998, 54, 581.
31. Enz, R. Biol. Chem., 2001, 382, 1111.
32. Di Giovanni, G.; Di Mascio, M.; Di, M. V.; Esposito, E. J. Pharmacol. Exp. Ther., 1998, 287, 51.
33. Joyce, J.N. Pharmacol. Ther., 2001, 90, 231.
34. Kebabian, J.W.; Calne, D.B. Nature, 1979, 277, 93.
35. Rothman, R.B.; Vu, N.; Partilla, J.S.; Roth, B.L.; Hufeisen, S.J.; Compton-Toth, B.A.; Birkes, J.; Young, R.; Glennon, R.A. J. Pharmacol. Exp. Ther., 2003, 307, 138.
36. Marder, S.R.; Davis, J.M.; Chouinard, G. J. Clin. Psychiatry, 1997, 58, 538.
37. Tissot, R. Neuropsychobiology, 1975, 1, 243.
38. Meltzer, H.Y.; Matsubara, S.; Lee, J.C. Psychopharmacol. Bull., 1989, 25, 390.
39. Kerwin, R.; Taylor, D. CNS Drugs, 1996, 6, 71.
40. Shapiro, D.A.; Renock, S.; Arrington, E.; Chiodo, L.A.; Liu, L.X.; Sibley, D.R.; Roth, B.L.; Mailman, R. Neuropsychopharmacology, 2003,
41. Lambert, T.J.; Castle, D.J. Med. J. Aust., 2003, 178 Suppl., S57.
42. Bymaster, F.P.; Calligaro, D.O.; Falcone, J.F.; Marsh, R.D.; Moore, N.A.; Tye, N.C.; Seeman, P.; Wong, D.T. Neuropsychopharmacology, 1996, 14, 87.
43. Bitter, I.; Dossenbach, M.R.; Brook, S.; Feldman, P.D.; Metcalfe, S.; Gagiano, C.A.; Furedi, J.; Bartko, G.; Janka, Z.; Banki, C.M.; Kovacs, G.; Breier, A. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2004, 28, 173.
44. Dursun, S.M.; Gardner, D.M.; Bird, D.C.; Flinn, J. Can. J. Psychiatry, 1999, 44, 701.
45. Conley, R.R.; Tamminga, C.A.; Bartko, J.J.; Richardson, C.; Peszke, M.; Lingle, J.; Hegerty, J.; Love, R.; Gounaris, C.; Zaremba, S. Am. J. Psychiatry, 1998, 155, 914.
46. Lindenmayer, J.P.; Czobor, P.; Volavka, J.; Lieberman, J.A.; Citrome, L.; Sheitman, B.; Chakos, M.; McEvoy, J.P. J. Clin. Psychiatry, 2002, 63, 931.
47. de Paulis, T. Curr. Opin. Investig. Drugs, 2001, 2, 123.
48. Ichikawa, J.; Dai, J.; O'Laughlin, I.A.; Fowler, W.L.; Meltzer, H.Y. Neuropsychopharmacology, 2002, 26, 325.
49. Ichikawa, J.; Li, Z.; Dai, J.; Meltzer, M.Y. Brain Res., 2002, 956, 349.
50. Shannon, H.E.; Rasmussen, K.; Bymaster, F.P.; Hart, J.C.; Peters, S.C.; Swedberg, M.D.; Jeppesen, L.; Sheardown, M.J.; Sauerberg, P.; Fink-Jensen, A. Schizophr. Res., 2000, 42, 249.
51. Simosky, J.K.; Stevens, K.E.; Freedman, R. Curr. Drug Target CNS Neurol. Disord., 2002, 1, 149.
52. Ahlenius, S. Pharmacol. Toxicol., 1999, 84, 193.
53. Salmi, P.; Ahlenius, S. Eur. J. Pharmacol., 1996, 307, 27.
54. Jackson, D.M.; Wikstrom, H.; Liao, Y. Psychopharmacology (Berl.), 1998, 138, 213.
55. Cai, G.; Gurdal, H.; Smith, C.; Wang, H.Y.; Friedman, E. Mol. Pharmacol., 1999, 56, 989.
56. Tamminga, C.A. J. Neural Transm., 2002, 109, 411.
57. Kane, J.M.; Carson, W.H.; Saha, A.R.; McQuade, R.D.; Ingenito, G.G.; Zimbroff, D.L.; Ali, M.W. J. Clin. Psychiatry, 2002, 63, 763.
58. McGavin, J.K.; Goa, K.L. CNS Drugs, 2002, 16, 779.
59. Lawler, C.P.; Prioleau, C.; Lewis, M.M.; Mak, C.; Jiang, D.; Schetz, J.A.; Gonzalez, A.M.; Sibley, D.R.; Mailman, R.B. Neuropsychopharmacology, 1999, 20, 612.
60. Jordan, S.; Koprivica, V.; Chen, R.; Tottori, K.; Kikuchi, T.; Altar, C.A. Eur. J. Pharmacol., 2002, 441, 137.
61. Inoue, A.; Miki, S.; Seto, M.; Kikuchi, T.; Morita, S.; Ueda, H.; Misu, Y.; Nakata, Y. Eur. J. Pharmacol., 1997, 321, 105.
62. Burris, K.D.; Molski, T.F.; Xu, C.; Ryan, E.; Tottori, K.; Kikuchi, T.; Yocca, F.D.; Molinoff, P.B. J. Pharmacol. Exp. Ther., 2002, 302, 381.
63. Kikuchi, T.; Tottori, K.; Uwahodo, Y.; Hirose, T.; Miwa, T.; Oshiro, Y.; Morita, S. J. Pharmacol. Exp. Ther., 1995, 274, 329.
64. Oshiro, Y.; Sato, S.; Kurahashi, N.; Tanaka, T.; Kikuchi, T.; Tottori, K.; Uwahodo, Y.; Nishi, T. J. Med. Chem., 1998, 41, 658.
65. Marder, S.R.; McQuade, R.D.; Stock, E.; Kaplita, S.; Marcus, R.; Safferman, A.Z.; Saha, A.; Ali, M.; Iwamoto, T. Schizophr. Res., 2003, 61, 123.
66. Casey, D.E.; Carson, W.H.; Saha, A.R.; Liebeskind, A.; Ali, M.W.; Jody, D.; Ingenito, G.G. Psychopharmacology (Berl.), 2003, 166, 391.
67. Farde, L.; Nordstrom, A.L.; Wiesel, F.A.; Pauli, S.; Halldin, C.; Sedvall, G. Arch. Gen. Psychiatry, 1992, 49, 538.
68. Yokoi, F.; Grunder, G.; Biziere, K.; Stephane, M.; Dogan, A.S.; Dannals, R.F.; Ravert, H.; Suri, A.; Bramer, S.; Wong, D.F. Neuropsychopharmacology, 2002, 27, 248.
69. Stahl, S.M. J. Clin. Psychiatry, 2001, 62, 841.
70. Stahl, S.M. J. Clin. Psychiatry, 2001, 62, 923.
71. Nakai, S.; Hirose, T.; Uwahodo, Y.; Imaoka, T.; Okazaki, H.; Miwa, T.; Nakai, M.; Yamada, S.; Dunn, B.; Burris, K.D.; Molinoff, P.B.; Tottori, K.; Altar, C.A.; Kikuchi, T. Eur. J. Pharmacol., 2003, 472, 89.
72. Zorn, S.H.; Jones, S.B.; Ward, K.M.; Liston, D.R. Eur. J. Pharmacol., 1994, 269, R1.
73. Olianas, M.C.; Maullu, C.; Onali, P. Br. J. Pharmacol., 1997, 122, 401.
74. Zeng, X.P.; Le, F.; Richelson, E. Eur. J. Pharmacol., 1997, 321, 349.
75. Michal, P.; Lysikova, M.; El Fakahany, E.E.; Tucek, S. Eur. J. Pharmacol., 1999, 376, 119.
76. Olianas, M.C.; Maullu, C.; Onali, P. Neuropsychopharmacology, 1999, 20, 263.
77. Stanhope, K.J.; Mirza, N.R.; Bickerdike, M.J.; Bright, J.L.; Harrington, N.R.; Hesselink, M.B.; Kennett, G.A.; Lightowler, S.; Sheardown, M.J.; Syed, R.; Upton, R.L.; Wadsworth, G.; Weiss, S.M.; Wyatt, A. J. Pharmacol. Exp. Ther., 2001, 299, 782.
78. Newman-Tancredi, A.; Chaput, C.; Verriele, L.; Millan, M.J. Neuropharmacology, 1996, 35, 119.
79. Newman-Tancredi, A.; Gavaudan, S.; Conte, C.; Chaput, C.; Touzard, M.; Verriele, L.; Audinot, V.; Millan, M.J. Eur. J. Pharmacol., 1998, 355, 245.
80. Cosi, C.; Koek, W. Eur. J. Pharmacol., 2001, 433, 55.
81. Elliott, J.; Reynolds, G.P. Eur. J. Pharmacol., 1999, 386, 313.
82. Rollema, H.; Lu, Y.; Schmidt, A.W.; Zorn, S.H. Eur. J. Pharmacol., 1997, 338, R3.
83. Rollema, H.; Lu, Y.; Schmidt, A.W.; Sprouse, J.S.; Zorn, S.H. Biol. Psychiatry, 2000, 48, 229.
84. Ichikawa, J.; Meltzer, H.Y. Brain Res., 2000, 858, 252.
85. Herrick-Davis, K.; Grinde, E.; Teitler, M. J. Pharmacol. Exp. Ther., 2000, 295, 226.
86. Hietala, J.; Kuonnamaki, M.; Palvimaki, E.P.; Laakso, A.; Majasuo, H.; Syvalahti, E. Psychopharmacology (Berl.), 2001, 157, 180.
87. Rauser, L.; Savage, J.E.; Meltzer, H.Y.; Roth, B.L. J. Pharmacol. Exp. Ther., 2001, 299, 83.
88. Hewitt, K.N.; Lee, M.D.; Dourish, C.T.; Clifton, P.G. Pharmacol. Biochem. Behav., 2002, 71, 691.
89. Chou-Green, J.M.; Holscher, T.D.; Dallman, M.F.; Akana, S.F. Physiol. Behav., 2003, 79, 217.
90. Weiden, P.J.; Mackell, J.A.; McDonnell, D.D. Schizophr. Res., 2004, 66, 51.
91. Potkin, S.G.; Saha, A.R.; Kujawa, M.J.; Carson, W.H.; Ali, M.; Stock, E.; Stringfellow, J.; Ingenito, G.; Marder, S.R. Arch. Gen. Psychiatry, 2003, 60, 681.
92. Wong, D.F.; Gjedde, A.; Wagner, H.N. Jr.; Dannals, R.F.; Douglass, K.H.; Links, J.M.; Kuhar, M.J. J. Cereb. Blood Flow Metab., 1986, 6, 147.
93. Gjedde, A.; Wong, D.F. Neurosurg. Rev., 1987, 10, 9.
94. Kapur, S.; VanderSpek, S.C.; Brownlee, B.A.; Nobrega, J.N. J. Pharmacol. Exp. Ther., 2003, 36, 625.
95. Turrone, P.; Remington, G.; Kapur, S.; Nobrega, J.N. Neuropsychopharmacology, 2003, 28, 1433.
96. Sutcliffe, J.G.; Foye, P.E.; Erlander, M.G.; Hilbush, B.S.; Bodzin, L.J.; Durham, J.T.; Hasel, K.W. Proc. Natl. Acad. Sci. USA, 2000, 97, 1976.
97. Thomas, E.A.; Danielson, P.E.; Nelson, P.A.; Pribyl, T.M.; Hilbush, B.S.; Hasel, K.W.; Sutcliffe, J.G. J. Neurochem., 2001, 76, 789.
98. Thomas, E.A.; Copolov, D.L.; Sutcliffe, J.G. Curr. Mol. Med., 2003, 3, 408.
99. Thomas, E.A.; Dean, B.; Pavey, G.; Sutcliffe, J.G. Proc. Natl. Acad. Sci. USA, 2001, 98, 4066.
100. Dean, B.; Laws, S.M.; Hone, E.; Taddei, K.; Scarr, E.; Thomas, E.A.; Harper, C.; McClean, C.; Masters, C.; Lautenschlager, N.; Gandy, S.E.; Martins, R.N. Biol. Psychiatry, 2003, 54, 616.
101. Mimmack, M.L.; Ryan, M.; Baba, H.; Navarro-Ruiz, J.; Iritani, S.; Faull, R.L.; McKenna, P.J.; Jones, P.B.; Arai, H.; Starkey, M.; Emson, P.C.; Bahn, S. Proc. Natl. Acad. Sci. USA, 2002, 99, 4680.
102. Kontkanen, O.; Toronen, P.; Lakso, M.; Wong, G.; Castren, E. J. Neurochem., 2002, 83, 1043.
103. McCormick, F. Mol. Reprod. Dev., 1995, 42, 500.
104. Kidokoro, Y. Neurosignals., 2003, 12, 13.
105. Fisher, H.; Braun, J.E. Can. J. Physiol. Pharmacol., 2000, 78, 856.
106. Glavan, G.; Zorec, R.; Babic, K.; Sket, D.; Zivin, M. Neuroreport, 2000, 11, 4043.
107. Ardizzone, T.D.; Bradley, R.J.; Freeman, A.M. III; Dwyer, D.S. Brain Res., 2001, 923, 82.
108. Lean, M.E.; Pajonk, F.G. Diabetes Care, 2003, 26, 1597.
109. Dwyer, D.S.; Donohoe, D. Pharmacol. Biochem. Behav., 2003, 75, 255.
110. Lindenmayer, J.P.; Czobor, P.; Volavka, J.; Citrome, L.; Sheitman, B.; McEvoy, J.P.; Cooper, T.B.; Chakos, M.; Lieberman, J.A. Am. J. Psychiatry, 2003, 160, 290.
111. Haro, J.M.; Edgell, E.T.; Frewer, P.; Alonso, J.; Jones, P.B. Acta Psychiatr. Scand. Suppl, 2003, 7.
112. Luchins, D.J.; Freed, W.J.; Wyatt, R.J. Am. J. Psychiatry, 1980, 137, 1395.
113. Goudie, A.J. J. Psychopharmacol., 2000, 14, 188.
114. Prasad, C. Schizophr. Res., 1988, 1, 411.
115. Mazurek, M.F.; Savedia, S.M.; Bobba, R.S.; Garside, S.; Rosebush, P.I. J. Neurol. Neurosurg. Psychiatry, 1998, 64, 799.
116. Nyberg, S.; Farde, L.; Halldin, C. Arch. Gen. Psychiatry, 1997, 54, 953.
117. Scarr, E.; Parkin, F.M.; Pavey, G.; Dean, B. Life Sci., 2002, 70, 2699.
118. See, R.E.; Chapman, M.A. Eur. J. Pharmacol., 1994, 263, 269.
119. Calabresi, P.; Centonze, D.; Cupini, L.M.; Costa, C.; Pisani, F.; Bernardi, G. Neurobiol. Dis., 2003, 12, 82.
120. Haleem, D.J.; Khan, N.H. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2003, 27, 645.
121. Grimm, J.W.; Chapman, M.A.; Zahm, D.S.; See, R.E. Synapse, 2001, 39, 51.
122. Radke, J.M.; MacLennan, A.J.; Beinfeld, M.C.; Bissette, G.; Nemeroff, C.B.; Vincent, S.R.; Fibiger, H.C. Brain Res., 1989, 480, 178.
123. McCobb, D.P.; Haydon, P.G.; Kater, S.B. J. Neurosci. Res., 1988, 19, 19.
124. Haydon, P.G.; McCobb, D.P.; Kater, S.B. J. Neurobiol., 1987, 18, 197.
125. Small, D.H.; Reed, G.; Whitefield, B.; Nurcombe, V. J. Neurosci., 1995, 15, 144.
126. Andersson, C.; Hamer, R.M.; Lawler, C.P.; Mailman, R.B.; Lieberman, J.A. Neuropsychopharmacology, 2002, 27, 143.
127. Bubser, M.; Deutch, A.Y. Eur. J. Neurosci., 2002, 15, 713.
128. O'Donnell, P.; Grace, A.A. Neuroscience, 1995, 66, 763.
129. Benes, F.M.; Paskevich, P.A.; Davidson, J.; Domesick, V.B. Brain Res., 1985, 348, 15.
130. Pantelis, C.; Velakoulis, D.; McGorry, P.D.; Wood, S.J.; Suckling, J.; Phillips, L.J.; Yung, A.R.; Bullmore, E.T.; Brewer, W.; Soulsby, B.; Desmond, P.; McGuire, P.K. Lancet, 2003, 361, 281.